An Efficacy and Safety Study of NBI-56418 in Endometriosis

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: January 24, 2008
Last updated: January 2, 2013
Last verified: January 2013

This study is designed to see how a research compound (NBI- 56418) works compared to placebo (also known as a sugar pill) in women with endometriosis and to see the effect, if any, on bone mineral density.

Condition Intervention Phase
Endometriosis, Pain
Drug: NBI-56418
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Dysmenorrhea Assessments [ Time Frame: Daily assessments over 12 weeks ] [ Designated as safety issue: No ]
  • Nonmenstrual pelvic pain assessments [ Time Frame: Daily assessments over 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Bone Mineral Density [ Time Frame: Week 12 ] [ Designated as safety issue: Yes ]
  • Change in Bone Mineral Density [ Time Frame: Week 24 ] [ Designated as safety issue: Yes ]
  • Change in Bone Mineral Density [ Time Frame: Week 48 (if needed) ] [ Designated as safety issue: Yes ]

Enrollment: 155
Study Start Date: December 2007
Study Completion Date: August 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
NBI-56418 - 150 mg tablet dose level
Drug: NBI-56418
150 mg tablet
Experimental: 2
NBI-56418 - 250 mg tablet dose level
Drug: NBI-56418
250 mg tablet
Placebo Comparator: 3
Placebo to match
Drug: placebo
placebo tablet to match NBI-56418

Detailed Description:

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of NBI-56418 at two dose levels administered once daily for up to 6 months. Approximately 150 subjects will be randomized (1:1:1) to one of the following treatment groups for the first 12 weeks of dosing: 150 mg NBI-56418 q.d.; 250 mg NBI-56418 q.d; or placebo q.d. Following 12 weeks of dosing, subjects will continue in the study for an additional 12 weeks; subjects randomized to NBI-56418 will continue to receive their assigned dose and subjects randomized to placebo will be re-randomized to receive one of the two doses of NBI-56418 for 12 weeks in a double-blind fashion. The effect of NBI-56418 treatment on bone mineral density (BMD) following 6 months of treatment with NBI-56418.


Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Be female, aged 18 to 49 years, inclusive
  • Have moderate to severe pelvic pain due to endometriosis
  • Have been surgically (laparoscopy) diagnosed with endometriosis within the last 8 years and have recurrent or persistent endometriosis symptoms
  • Have regular menstrual cycle
  • Have a Body Mass Index (BMI) of 18 to 36 kg/m2, inclusive
  • Agree to use two forms of non-hormonal contraception during the study

Exclusion Criteria

  • Are currently receiving GnRH agonist or GnRH antagonist or have received any of these agents within 6 months of the start of screening
  • Are currently receiving DMPA-SC or DMPA-IM or have received any of these agents within 3 months of the start of screening
  • Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month
  • Have had surgery for endometriosis within the last month
  • Have had a hysterectomy or bilateral oophorectomy
  • Are using systemic steroids on a chronic or regular basis within 3 months
  • Have uterine fibroids ≥3 cm in diameter
  • Have pelvic pain that is not caused by endometriosis
  • Have unstable medical condition or chronic disease
  • Have been pregnant within the last six months
  • Currently breast feeding
  Contacts and Locations
Please refer to this study by its identifier: NCT00619866

  Hide Study Locations
United States, Alabama
Site Reference ID/Investigator# 58185
Dothan, Alabama, United States, 36303
Site Reference ID/Investigator# 58194
Huntsville, Alabama, United States, 35801
United States, Arizona
Site Reference ID/Investigator# 57988
Phoenix, Arizona, United States, 85015
United States, Arkansas
Site Reference ID/Investigator# 57991
Little Rock, Arkansas, United States, 72205
United States, California
Site Reference ID/Investigator# 58187
Encinitas, California, United States, 92024
Site Reference ID/Investigator# 57989
San Diego, California, United States, 92108
Site Reference ID/Investigator# 58166
Vallejo, California, United States, 94589
United States, Colorado
Site Reference ID/Investigator# 58182
Denver, Colorado, United States, 80220
United States, Connecticut
Site Reference ID/Investigator# 58002
Milford, Connecticut, United States, 06460
Site Reference ID/Investigator# 58186
Waterbury, Connecticut, United States, 06708
United States, Florida
Site Reference ID/Investigator# 57980
Boynton Beach, Florida, United States, 33472
Site Reference ID/Investigator# 58005
Clearwater, Florida, United States, 33759
Site Reference ID/Investigator# 58189
Jacksonville, Florida, United States, 32216
Site Reference ID/Investigator# 58007
Tampa, Florida, United States, 33613
Site Reference ID/Investigator# 57998
West Palm Beach, Florida, United States, 33409-3509
United States, Illinois
Site Reference ID/Investigator# 57985
Oak Brook, Illinois, United States, 60523
United States, Indiana
Site Reference ID/Investigator# 57981
South Bend, Indiana, United States, 46601
United States, Kansas
Site Reference ID/Investigator# 58003
Wichita, Kansas, United States, 67208
United States, Kentucky
Site Reference ID/Investigator# 57986
Louisville, Kentucky, United States, 40291
United States, Maryland
Site Reference ID/Investigator# 57997
Baltimore, Maryland, United States, 21229
United States, Michigan
Site Reference ID/Investigator# 57984
Detroit, Michigan, United States, 48201
United States, New Jersey
Site Reference ID/Investigator# 58163
Plainsboro, New Jersey, United States, 08536
United States, North Carolina
Site Reference ID/Investigator# 58191
Charlotte, North Carolina, United States, 28209
Site Reference ID/Investigator# 57993
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Site Reference ID/Investigator# 57999
Cincinnati, Ohio, United States, 45267
Site Reference ID/Investigator# 57995
Columbus, Ohio, United States, 43213
Site Reference ID/Investigator# 58183
Dayton, Ohio, United States, 45408
Site Reference ID/Investigator# 58006
Englewood, Ohio, United States, 45322
United States, Oklahoma
Site Reference ID/Investigator# 58004
Oklahoma City, Oklahoma, United States, 73112
United States, Oregon
Site Reference ID/Investigator# 58000
Medford, Oregon, United States, 97504
Site Reference ID/Investigator# 57992
Portland, Oregon, United States, 97239
United States, Pennsylvania
Site Reference ID/Investigator# 58184
Pittsburgh, Pennsylvania, United States, 15206
United States, South Carolina
Site Reference ID/Investigator# 58193
Gaffney, South Carolina, United States, 29340
Site Reference ID/Investigator# 57987
Greenville, South Carolina, United States, 29615
United States, Tennessee
Site Reference ID/Investigator# 58165
Chattanooga, Tennessee, United States, 37404
Site Reference ID/Investigator# 57982
Nashville, Tennessee, United States, 37203
United States, Texas
Site Reference ID/Investigator# 58192
Austin, Texas, United States, 78737
Site Reference ID/Investigator# 58168
Austin, Texas, United States, 78705
Site Reference ID/Investigator# 57983
Dallas, Texas, United States, 75390-8852
Site Reference ID/Investigator# 57994
Houston, Texas, United States, 77030
Site Reference ID/Investigator# 58190
Houston, Texas, United States, 77030
Site Reference ID/Investigator# 58164
San Antonio, Texas, United States, 78229
Site Reference ID/Investigator# 58162
Schertz, Texas, United States, 78154
United States, Utah
Site Reference ID/Investigator# 58167
Pleasant Grove, Utah, United States, 84062
Site Reference ID/Investigator# 58001
Sandy, Utah, United States, 84070
United States, Vermont
Site Reference ID/Investigator# 58188
Burlington, Vermont, United States, 05405
United States, Virginia
Site Reference ID/Investigator# 57996
Richmond, Virginia, United States, 23225
Site Reference ID/Investigator# 58169
Richmond, Virginia, United States, 23233
United States, Washington
Site Reference ID/Investigator# 57990
Seattle, Washington, United States, 98105
United States, Wisconsin
Site Reference ID/Investigator# 57979
LaCrosse, Wisconsin, United States, 54601
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Laura Williams, MD AbbVie Laboratories
  More Information

No publications provided

Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier: NCT00619866     History of Changes
Other Study ID Numbers: NBI-56418-0702
Study First Received: January 24, 2008
Last Updated: January 2, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by AbbVie:
bone mineral density
Pelvic Pain

Additional relevant MeSH terms:
Genital Diseases, Female processed this record on April 17, 2014